Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:05:21.898Z.
Calculation as of: 2026-10-06T18:05:21.898Z.
Quote observation: 2026-10-06T18:00:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 033b533528001a3499036996a5838431eca9b2abd512acbebbb4929ff412c5bb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$770.68M
EV/Sales Ratio
19.03x
TTM Avg
12.42x
3Y Avg
202.88x
5Y Avg
983.65x
Market Cap
$778.29M
EV/Sales Ratio
1.22x
TTM Avg
0.95x
3Y Avg
1.06x
5Y Avg
1.24x
Market Cap
$766.61M
EV/Sales Ratio
3.35x
TTM Avg
2.72x
3Y Avg
3.17x
5Y Avg
4.51x
Market Cap
$764.64M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$782.66M
EV/Sales Ratio
4.12x
TTM Avg
5.53x
3Y Avg
1615.59x
5Y Avg
1480.74x
Market Cap
$789.52M
EV/Sales Ratio
6.28x
TTM Avg
5.90x
3Y Avg
8.86x
5Y Avg
33.86x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | $773.34M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.68M | 19.03x | 12.42x | 202.88x | 983.65x |
| Varex Imaging Corporation (VREX)vs › | $778.29M | 1.22x | 0.95x | 1.06x | 1.24x |
| Mesa Laboratories, Inc. (MLAB)vs › | $766.61M | 3.35x | 2.72x | 3.17x | 4.51x |
| Attovia Therapeutics, Inc. (ATTO)vs › | $764.64M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $764.80M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $782.66M | 4.12x | 5.53x | 1615.59x | 1480.74x |
| AdaptHealth Corp. (AHCO)vs › | $785.71M | 0.93x | 1.16x | 1.13x | 1.47x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $789.52M | 6.28x | 5.90x | 8.86x | 33.86x |
| Design Therapeutics, Inc. (DSGN)vs › | $745.42M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
